Learn More About the PROSERA Study
Now enrolling: The PROSERA phase 3 study of seralutinib in adults with pulmonary arterial hypertension.
Current treatment patterns in pulmonary arterial hypertension (PAH): Real-world data from a contemporary U.S. Physician survey